ReviewSeminars in respiratory and critical care medicine2023
Diagnosis and Management of Cystic Fibrosis Exacerbations.
Review in Seminars in respiratory and critical care medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Association between OLD and IBD: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Correlates of FEV₁ deficit in pulmonary exacerbations of cystic fibrosis and associated clinical outcomes.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2026Trial
- Remodeling the pathological airway: advanced nanotechnology for diagnostics and therapeutics in cystic fibrosis.Journal of nanobiotechnology · 2026Review
- Contribution of two-component regulatory systems to the acute-to-chronic infection transition ofJournal of bacteriology · 2026Review
- Acute exposure to fine ambient particulate matter and pulmonary exacerbations in cystic fibrosis: A case-crossover study.Atmospheric Environment: X · 2026Article
- Measurement properties of the Polish version of the Cystic Fibrosis Questionnaire Revised 14+ in the adult population.Scientific reports · 2025Article
- Polymerized cyclodextrin microparticles for sustained antibiotic delivery in lung infections.Journal of biomedical materials research. Part A · 2024Article
- Predicting lung function decline in cystic fibrosis: the impact of initiating ivacaftor therapy.Respiratory research · 2024Article
- Forced oscillometry technique in the assessment of adults with cystic fibrosis treated for a pulmonary exacerbation, a pilot feasibility study.Chronic respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
With the improving survival of cystic fibrosis (CF) patients and the advent of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) therapy, the clinical spectrum of this complex multisystem disease continues to evolve. One of the most important clinical events for patients with CF in the course of this disease is acute pulmonary exacerbation (PEx). Clinical and microbial epidemiology studies of CF PEx continue to provide important insight into the disease course, prognosis, and complications. This work has now led to several large-scale clinical trials designed to clarify the treatment paradigm for CF PEx. The primary goal of this review is to provide a summary and update of the pathophysiology, clinical and microbial epidemiology, outcome and treatment of CF PEx, biomarkers for exacerbation, and the impact of highly effective modulator therapy on these events moving forward.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.